Q-omics provides the consensus-scored MYO7A profile across patient tissues and cancer cell-line models. MYO7A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MYO7A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MYO7A RNA expression shows 15,981 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, HNSC, and THYM as cancer lineages where MYO7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO7A survival associations across molecular data types. MYO7A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO7A RNA expression–survival associations across cancer types. High MYO7A expression shows unfavorable associations in LGG and LAML, but favorable associations in SKCM, BRCA, BLCA and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MYO7A RNA expression.
This table summarizes MYO7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYO7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO7A shows higher tumor expression in HNSC, KIRC, COAD, LUAD, STAD and LUSC. The HNSC box plot shows higher MYO7A RNA expression in tumor versus normal tissue (log2 FC = +1.001, t-test p < 0.001).
This table shows molecular features associated with MYO7A in patient tissues and cancer cell lines. In patient samples, MYO7A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
